Mortality Rates after Multifactorial Primary Prevention of Cardiovascular Diseases

References

• Salonen J. T., Puska P., Mustaniemi H. Changes in morbidity and mortality during comprehensive community programme to control cardiovascular diseases during 1972–1977 in North Karelia. Br Med J 1979; 2: 1178–83
   PubMed Web of Science ®Google Scholar
• World Health Organization European Collaborative Group. Multifactorial trial in the prevention of coronary heart disease. 3. Incidence and mortality results. Eur Heart J 1983; 4: 141–7
   PubMed Web of Science ®Google Scholar
• Hjermann I., Byre K. V., Holme I., Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a Randomised Trial in Healthy Men. Lancet 1981; 11: 1303–10
   Google Scholar
• Hjermann I., Holme I., Leren P. Oslo Study Diet and Anti-smoking Trial. Results after 102 months. Am J Med 1986; 80(suppl 2A)7–11
   PubMedGoogle Scholar
• Komitzer M., de Backer G., Dramaix M., et al. Belgian Heart Disease Prevention Project: Incidence and mortality results. Lancet 1983; 1: 1066–70
   PubMedGoogle Scholar
• Rose G., Tunstall-Pedoe H. D., Heller R. F. UK Heart Disease Prevention Project: Incidence and mortality results. Lancet 1983; 1: 1062–5
   PubMed Web of Science ®Google Scholar
• Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention trial: Risk factor changes and mortality results. JAMA 1982; 248: 1465–77
   PubMed Web of Science ®Google Scholar
• Keys A., Aravanis C., Blackburn H., et al. Probability of middle-aged men developing coronary heart disease in five years. Circulation 1972; 45: 815–28
   PubMed Web of Science ®Google Scholar
• Miettinen T. A., Huttunen J. K., Naukkarinen V., et al. Multifactorial primary prevention of cardiovascular disease in middle-aged men. Risk factor changes, incidence and mortality. JAMA 1985; 254: 2097–102
   PubMed Web of Science ®Google Scholar
• Naukkarinen V. The feasibility of administering preventive treatment for coronary heart disease to middle-aged men. University of Helsinki, Helsinki 1981, Academic Dissertation
   Google Scholar
• BMDP Statistical Software, W. J. Dickson. University of California Press, Berkeley 1985
   Google Scholar
• Armitage P., Berry G. Statistical methods in medical research2nd ed. Blackwell Scientific Publications. 1987; 119
   Google Scholar
• Cox D. R. Some procedures connected with logistic qualitative response curve. Research papers in statistics, F. N. David. John Wiley & Sons, New York 1966; 55
   Google Scholar
• Multiple Risk Factor Intervention Trial Research Group. Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial. Am J Cardiol 1985; 55: 1–15
   PubMed Web of Science ®Google Scholar
• Wilhelmsen L., Berglund G., Elmfeldt D., et al. The multifac-tor primary prevention trial in Goteborg, Sweden. Eur Heart J 1986; 7: 279–88
   PubMed Web of Science ®Google Scholar
• Frishman W. H., Furberg C. D., Friedewald W. T. β-adrenergic blockade for survivors of acute myocardial infarction. N Engl J Med 1984; 310: 830–7
   PubMed Web of Science ®Google Scholar
• β-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 1982; 247: 1707–14
   PubMed Web of Science ®Google Scholar
• Australian and Swedish Pindolol Study Group. The effect of pindolol on the two years mortality after complicated myocardial infarction. Eur Heart J 1983; 4: 367–75
   PubMed Web of Science ®Google Scholar
• Pedersen TR for the Norwegian Multicenter Study Group. Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. N Engl J Med 1985; 313: 1055–8
   PubMedGoogle Scholar
• Coronary heart disease in seven countries. Circulation 1970; 41(suppl 1), Keys A., ed.
   Google Scholar
• Keys A., Aravanis C., Blackburn H., et al. Seven countries. A multivariate analysis of death and coronary heart disease. Harvard University Press, Cambridge 1980; 1–381
   Google Scholar
• Salonen J. T., Puska P., Kottke T. E., et al. Decline in mortality from coronary heart disease in Finland from 1969 to 1979. Br Med J 1983; 286: 1857–60
   PubMed Web of Science ®Google Scholar
• Study group, European Atherosclerosis Society. The recognition and managemet of hyperlipidaemia in adults: a policy statement of the European Atherosclerosis Society. Eur Heart J 1988; 9: 571–600
   PubMed Web of Science ®Google Scholar
• Helgeland A. Treatment of mild hypertension. A 5-year controlled drug trial: The Oslo Study. Am J Med 1980; 69: 725–32
   PubMed Web of Science ®Google Scholar
• Leren P., Helgeland A. Coronary heart disease and treatment of hypertension. Some Oslo Study data. Am J Med 1986; 80(suppl 2A)3–6
   PubMedGoogle Scholar
• Management Committee on the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet 1982; 1: 185–91
   PubMedGoogle Scholar
• Medical Research Council Working Party. MRC trial of treament of mild hypertension: principal results. Br Med J 1985; 291: 97–104
   PubMed Web of Science ®Google Scholar
• Anonymous. The hypertension - CHD dilemma [Editorial]. Acta Med Scand 1985; 217: 145–7
   Google Scholar
• Lehtonen A. Effects of β-blockers on plasma lipids during antihypertensive therapy. J Cardiovasc Pharmacol 1985; 7: S110–4
   Google Scholar
• Weinberg M. H. Antihypertensive therapy and lipids. Evidence, mechanisms and implications. Arch Intern Med 1985; 145: 1102–5
   PubMedGoogle Scholar
• Leren P., Foss P. O., Helgeland A., et al. Effect of propranolol and prazosin on blood lipids. The Oslo Study. Lancet 1980; 11: 4–6
   Google Scholar
• Day J. L., Metcalfe J., Simpson N., Lowenthal L. Adrenergic mechanisms in the control of plasma lipids in man. Am J Med 1984; 76(suppl 2A)94–6
   PubMedGoogle Scholar
• Van Brummelen P. The relevance of intrinsic sympathomimetic activity for 0-blocker-induced changes in plasma lipids. J Cardiovasc Pharmacol 1983; 5: S50–5
   Google Scholar
• Leren P., Foss O. P., Helgeland A., Hjermann I., Holme J. Effect of pindolol and hydrochlorthiazide on blood lipids. The Oslo Study. Clin Trial J 1981; 18: 254–61
   Google Scholar
• Lasser N. L., Grandite G., Caggiula A. W. Effects of antihypertensive therapy on plasma lipids in the Multiple Risk Factor Intervention Trial. Am J Med 1984; 76(suppl 2A)52–66
   PubMed Web of Science ®Google Scholar
• Helgeland A., Hjermann I., Holme I., Leren P. Serum triglycerides and serum uric acid in untreated and thiazide treated patients with mild hypertension. The Oslo Study. Am J Med 1978; 64: 34–8
   PubMed Web of Science ®Google Scholar
• Lipid Research Clinic Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351–64
   PubMed Web of Science ®Google Scholar
• Frick M. H., Elo O., Haapa K., Heinonen O. P., Heinsalmi P., Helo P., Huttunen J. K., et al. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237–45
   PubMed Web of Science ®Google Scholar
• Committee of Principal Investigators. WHO Cooperative Trial on Primary Prevention of Ischemic Heart Disease with Clofibrate to Lower Serum Cholesterol: Mortality follow-up. Lancet 1980; 11: 379–85
   Google Scholar
• Committee of Principal Investigators. WHO Cooperative Trial on Primary Prevention of Ischemic Heart Disease with Clofibrate to Lower Serum Cholesterol: Final mortality follow-up. Lancet 1984; 11: 600–4
   Google Scholar
• Miettinen T. A., Huttunen J. K., Strandberg T., et al. Lowered HDL-cholesterol and incidence of ischaemic heart disease. Lancet 1981; 11: 478
   Google Scholar
• Carew T. E., Schwenke D. C., Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: Evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 1987; 84: 7725–9
   PubMed Web of Science ®Google Scholar
• Weiss R., Schwartzkopff W. Probucol in the treatment of type II A and II B hyperlipoproteinemia. Abstracts of the IX International symposium on drugs affecting lipid metabolism. Lorenzini Foundation, Florence 1986; 47
   Google Scholar
• Naukkarinen V., Strandberg T., Vanhanen H, Miettinen T A. Probucol-induced electrocardiographic changes in a five-year primary prevention of vascular diseases. Curr Ther Res 1989; 45: 1–6
   Google Scholar
• McCormick J., Skrabanok P. Coronary heart disease is not preventable by population interventions. Lancet 1988; ii: 839–41
   Google Scholar